Author:
Bugarin Cristina,Antolini Laura,Buracchi Chiara,Matarraz Sergio,Coliva Tiziana Angela,Van der Velden Vincent H.,Szczepanski Tomasz,Da Costa Elaine Sobral,Van der Sluijs Alita,Novakova Michaela,Mejstrikova Ester,Nierkens Stefan,De Mello Fabiana Vieira,Fernandez Paula,Aanei Carmen,Sędek Łukasz,Strocchio Luisa,Masetti Riccardo,Sainati Laura,Philippé Jan,Valsecchi Maria Grazia,Locatelli Franco,Van Dongen Jacques J.M.,Biondi Andrea,Orfao Alberto,Gaipa Giuseppe
Abstract
Diagnostic criteria for juvenile myelomonocytic leukemia (JMML) are currently well defined, however in some patients diagnosis still remains a challenge. Flow cytometry is a well established tool for diagnosis and follow-up of hematological malignancies, nevertheless it is not routinely used for JMML diagnosis. Herewith, we characterized the CD34+ hematopoietic precursor cells collected from 31 children with JMML using a combination of standardized EuroFlow antibody panels to assess the ability to discriminate JMML cells from normal/reactive bone marrow cell as controls (n=29) or from cells of children with other hematological diseases mimicking JMML (n=9). CD34+ precursors in JMML showed markedly reduced B-cell and erythroid-committed precursors compared to controls, whereas monocytic and CD7+ lymphoid precursors were significantly expanded. Moreover, aberrant immunophenotypes were consistently present in CD34+ precursors in JMML, while they were virtually absent in controls. Multivariate logistic regression analysis showed that combined assessment of the number of CD34+CD7+ lymphoid precursors and CD34+ aberrant precursors or erythroid precursors had a great potential in discriminating JMMLs versus controls. Importantly our scoring model allowed highly efficient discrimination of truly JMML versus patients with JMML-like diseases. In conclusion, we show for the first time that CD34+ precursors from JMML patients display a unique immunophenotypic profile which might contribute to a fast and accurate diagnosis of JMML worldwide by applying an easy to standardize single eight-color antibody combination.
Publisher
Ferrata Storti Foundation (Haematologica)
Reference40 articles.
1. Emanuel P, Bates L, Castleberry R, Gualtieri R, Zuckerman K. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991; 77(5):925-929.
2. Freedman MH, Cohen A, Grunberger T. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol. 1992; 80(1):40-48.
3. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: Incidence and predisposing conditions. Leukemia. 1995; 9(9):1569-1572.
4. Baumann I, Bennett JM, Niemeyer CM. Juvenile myelomonocytic leukemia. 2017;89-92.
5. Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.